Cinrebafusp alfa

DB18402InvestigationalProtein Based Therapies

Cinrebafusp alfa: Overview.

Mechanism: Pharmacologically active on Receptor tyrosine-protein kinase erbB-2 and Tumor necrosis factor receptor superfamily member 9
Curator reviewed
Also known as: (S228>P,F234>A,L235>A) IMMUNOGLOBULIN G4-KAPPA (CHIMERIC HUMAN-MUS MUSCULUS, ANTI-(RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2, ERBB2, HER2)) FUSED ON BOTH HEAVY CHAINS (1-447, 1''-447'') VIA A (G4S)3 LINKER (448-462, 448''-462'') TO A CD137 (TUMOR NECROSIS · Fus: mab humanized (igg4) s228p, f234a, l235a anti p04626 (erbb2_human)rprot p80188 (ngal_human) anti q07011 (tnr9_human) (prs343) · IMMUNOGLOBULIN G4 (228-PROLINE, 234-ALANINE, 235-ALANINE), ANTI-(HUMAN TYROSINE KINASE RECEPTOR HER2) (HUMAN-MUS MUSCULUS MONOCLONAL PRS-343 .GAMMA.4-CHAIN) FUSION PROTEIN PEPTIDE (SYNTHETIC 15-AMINO ACID LINKER) FUSION PROTEIN WITH LIPOCALIN 2 (HUMAN MU
Code names: PRS-343

Resolves to

Compound

Targets

What you can answer from here — as of July 09, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Cinrebafusp alfa, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.